ClinicalTrials.gg
Active, not recruitingNCT05068830ExPlasUpdated Apr 15, 2026

Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease

A Phase 2 interventional study of ExPlas and Octaplasma in Alzheimer Disease, sponsored by Norwegian University of Science and Technology. Active, not recruiting at 1 site in Norway. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Norwegian University of Science and Technology · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Alzheimer Disease with a site in Norway — 11 open to participants now, 15 under way, none of them phase 3. Alzheimer Disease · Norway.

Planned enrollment
27th of 37
60 · median 187
Started
2021
with 1 other
Phase 2
10 of 43
3 open now
Primary completion
2027-03
later than 6 of 14 live
Registered
29th of 43
by date
Lead sponsor
3 of 43
Norwegian University of Science and Technology

Among the 43 studies in Alzheimer Disease with a site in Norway, this one is the 27th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2021, is one of 10 in phase 2, reaches primary completion later than 6 of the 14 other live ones, and was the 29th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

11 of the 43 studies in Alzheimer Disease with a site in Norway are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Alzheimer Disease with a site in Norway, or all of them as a file.
02

Study summary

Introduction Given that exercise training reduces the risk of developing Alzheimer's disease (AD), induces changes in the blood composition and has widespread systemic benefits, it is reasonable to hypothesize that exercised plasma may have rejuvenative properties. The main objective is to test safety and tolerability of transfusing exercised plasma (ExPlas) from young, healthy, fit adults to patients with early AD. The study is a pilot for a future efficacy study. The key secondary objectives are examining the effect of plasma transfusions on cognitive function, fitness level, vascular risk profile, assessment of cerebral blood flow and hippocampal volume, quality of life, functional connectivity assessed by resting state functional MRI and biomarkers in blood and cerebrospinal fluid.

Methods and analysis ExPlas is a double-blinded, randomized controlled clinical single center trial. Patients aged 50-75 years with diagnosis mild cognitive impairment or early AD will be recruited from two Norwegian hospitals. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max >50 mL/kg/min). All units will be virus inactivated by the Intercept method in accordance with procedures at St. Olavs Hospital. Comparison with isotonic saline allows differentiation from a non-blood product. The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions divided over three 4-weeks periods during study year-1. Follow-up examinations after 2 and 5 years after baseline is also planned.

Ethics and dissemination Written informed consent will be obtained from all participants and participation is voluntary. All participants have a next of kin who will follow them throughout the study and represent the patient's interest. The study is approved by the Regional Committee for Medical and Health Research Ethics (REK 2018/702) and the Norwegian Medicines Agency (EudraCT No. 2018-000148-24).

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Exercise therapy
  • Blood transfusion
  • Plasma
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patient inclusion criteria:

  • Diagnosis AD in early phase according to the IWG-2 criteria.
  • (MMSE) Score ≥20.
  • In-vivo evidence of Alzheimer´s pathology (one of the following):

    • Decreased Aβ42 together with increased t-tau or p-tau in CSF.
    • Increased tracer retention on amyloid PET.
  • Availability of a next of kin who knows the patient well and is willing to accompany the subject to all trial visits and give information about the patients functional level.
  • Signed .
  • The patient is judged fitted for the study and capable to cooperate in treatment and follow-up.
  • Ability to communicate in Norwegian or another Scandinavian language.

Patient exclusion criteria:

  • Pregnancy or unwilling to use adequate for the duration of and 6 months beyond study participation. Defined according to Clinical Trial Facilitation Group document "Recommendations related to contraception and pregnancy testing in clinical trials".
  • Positive for , or at screening.
  • Not qualified to give consent at inclusion.
  • Any other condition judged to interfere with the safety of the patient or the intent and conduct of the study.

Related to medical history:

  • Stroke
  • Anaphylaxis
  • Prior adverse reaction to any human blood product
  • Any history of a blood coagulation disorder or hypercoagulability
  • Congestive heart failure, defined as any previous heart failure hospitalization, or current symptomatic heart failure in class ≥II with reduced, mid-range or preserved .
  • Coagulation defect or hypercoagulopathy
  • Uncontrolled hypertension
  • Renal failure
  • Prior intolerance to intravenous fluids
  • Recent history of uncontrolled atrial fibrillation
  • Bone marrow transplant
  • IgA deficiency
  • Severe protein S deficiency
  • Thrombocytopenia ( \< 40 x 10 to the power of 9/L)
  • for Octaplasma

Related to medications or other treatments:

  • Any concurrent use of anticoagulant therapy, clopidogrel or acetylsalicylic acid/Dipyridamol in combination.
  • Initiation or change in the dosage of a acetylcholine esterase inhibitor (AChEI) or memantine during the trial (week 0-52). Participants will be urged to start on AChEI when diagnosis is communicated, and must be on a stable dose for at least one month prior to screening.
  • Concurrent participation in another treatment trial for AD. If there was prior participation, the last dose of the agent must have been given at least 6 months prior to screening, except if the patient received placebo medication.
  • Treatment with any human blood product, including intravenous immunoglobulin, during the 6 months prior to screening or during the trial.
  • Concurrent daily treatment with benzodiazepines, typical or atypical antipsychotics, long-acting opioids, or other medications that is judged to interfere with cognition. Intermittent treatment with short-acting benzodiazepines or atypical antipsychotics may be permitted, provided that no dose is administered within 72 hours prior to cognitive assessment.

Related to magnetic resonance imaging:

  • Claustrophobia
  • Any metallic surgical implant, like a pacemaker or clip that is incompatible with MRI.

Certain metallic implants like joint replacements may be permitted, provided that specific manufacturer specifications are available, and that the device is known to be safe for 7T MRI. In case a patient is not eligible for the 7T scanner, the 3T scanner will be used.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Exercised plasma (ExPlas)

    Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 ExPlas transfusions during the time span of one year (weekly transfusions in 3 four-week periods)

    Drug: ExPlas

  • Active comparator
    Octaplasma

    Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 Octaplasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods)

    Drug: Octaplasma

  • Placebo comparator
    Saline

    Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods)

    Drug: Saline

Interventions

  • DrugExPlas

    ExPlas (plasma from fit donors) is a Investigational Medicinal Product. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max \>50 mL/kg/min) at the Blood Bank at St. Olavs Hospital. All unites will be virus inactivated by the Intercept method (Cerus corporation, US) in accordance with the procedures at Blood Bank at St. Olavs Hospital. The transfusion volume will be 200 mL at every time point. The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.

  • DrugOctaplasma

    Octaplasma is defined as a Investigational Medicinal Product. Octaplasma is human pooled plasma produced by Octapharma (Lachen, Switzerland). The transfusion volume will be 200 mL at every time point . The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.

  • DrugSaline

    Saline is provided by the hospital pharmacies in Central Norway. The infusion volume will be 200 mL at every time point. The main study consists of 6 rounds of examinations in addition to 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.

06

What researchers measure

Primary outcomes

  1. Number of patients with adverse events

    as a measure for safety and tolerability of the treatment

    Time frame: 1 year

  2. Number of subjects who comply with the research protocol

    as a measure for feasibility

    Time frame: 1 year

Secondary outcomes

  1. CERAD-test

    Change in performance in the CERAD (The Consortium to Establish a Registry for Alzheimer's Disease) Ten word Test. CERAD Word List consists of three test parts; immediate recall, delayed recall and recognition. The scoring range for immediate recall is 0-30, for delayed recall 0-10 and for recognition 0-20. Higher scores indicate better learning performance, memory performance and recognition performance.

    Time frame: 1, 2 and 5 years

  2. MMSE

    Change in the Mini-Mental State Examination Score. An MMSE score of ≥20 is criteria for inclusion. Higher scores \>28 indicate normal cognitive function. Scores in the middle range 25-27 may indicate cognitive impairment. Lower scores \<24 indicate cognitive impairment.

    Time frame: 1, 2, and 5 years

  3. Trail-Making test A and B

    Change in performance in Trail-Making test A and B. The Trail Making Tests are scored by how long it takes to complete the tests. Norms for completion time variate with age and educational level. Longer completion time indicates impaired visual attention, processing speed and executive function.

    Time frame: 1, 2, and 5 years

  4. Clock Drawing Test

    Change in scores in the Clock Drawing Test. The Clock Drawing Test has a scoring range 0-5. Higher scores indicate normal cognitive function. Lower scores \<4 may indicate cognitive impairment, spatial dysfunction or neglect.

    Time frame: 1, 2, and 5 years

  5. Controlled Oral Word Association Test (COWAT)-FAS

    Change in scores in Controlled Oral Word Association Test (COWAT)-FAS. Scoring is based on how many words the person produces within 1 minute. The minimum score is 0, and there is no maximum score. Higher scores indicate better verbal fluency. Scoring norms are based on the persons age and education level.

    Time frame: 1, 2, and 5 years

  6. Visual Object and Space Perception (VOSP) Silhouettes

    Change in scores in Visual Object and Space Perception (VOSP) Silhouettes. Visual Object and Space Perception (VOSP) Silhouettes has a scoring range 0-30. Higher scores \> 20 indicate normal visuospatial function, and lower scores \< 20 indicate visuospatial dysfunction.

    Time frame: 1, 2, and 5 years

  7. Clinical Dementia Rating Scale Global score and Sum of Boxes

    Change in Clinical Dementia Rating Scale Global score and Sum of Boxes. Clinical Dementia Rating Scale (CDR) is a clinical scale for the staging of dementia. The Global Score ranges dementia severity from 0-3. The Sum of Boxes ranges dementia severity from 0-18. Higher scores indicate more severe disease.

    Time frame: 1, 2, and 5 years

  8. The Lawton Instrumental Activities of Daily Living Scale (IADL)

    Change in The Lawton Instrumental Activities of Daily Living Scale (IADL). The Lawton Instrumental Activities of Daily Living Scale (IADL) evaluates the person's ability to perform complex everyday activities. The score ranges from 8-31. Higher scores indicate lower functional level.

    Time frame: 1, 2, and 5 years

  9. 6 minutes' walk test

    Change in 6 minutes' walk-test

    Time frame: 1, 2, and 5 years

  10. Functional MRI

    Change in/Reduced hippocampal atrophy and preservation of functional connectivity assessed by resting state functional MRI. A secondary aim is to identify any effect of treatment group on MRI markers of both neurodegenerative and cerebrovascular disease.

    Time frame: 1, 2, and 5 years

  11. SF-36

    Quality of Life SF-36 Questionnaire. Computer-based scoring services for the SF-36v2 are available through QualityMetric™ or its licensed certified vendors.

    Time frame: 1, 2, and 5 years

  12. Biomarker profile in blood

    Change in biomarkers in blood (APOE). As there exist no single ideal biomarker of AD this endpoint is partly exploratory. Biological material will be stored for future analysis in the search for new biomarkers.

    Time frame: 1, 2, and 5 years

  13. Biomarker profile in cerebrospinal fluid

    Change in biomarkers in cerebrospinal fluid (Amyloid Beta 1-42, Amyloid Beta 1-40, phosphor tau and total tau). As there exist no single ideal biomarker of AD this endpoint is partly exploratory. Biological material will be stored for future analysis in the search for new biomarkers.

    Time frame: 1, 2, and 5 years

  14. Echocardiography - Cardiac dimensions - Left ventricular end diastolic diameter

    Changes in cardiac dimensions - left ventricular end diastolic diameter (mm).

    Time frame: 1, 2, and 5 years

  15. Echocardiography - Cardiac dimensions - Right ventricular dimension

    Changes in cardiac dimensions - right ventricular dimension (mm).

    Time frame: 1, 2, and 5 years

  16. Echocardiography - Cardiac volumes - Left ventricular and diastolic volume.

    Changes in cardiac volumes - left ventricular and diastolic volume (mL).

    Time frame: 1, 2, and 5 years

  17. Echocardiography - Cardiac volumes - Right ventricular volume

    Changes in cardiac volumes. Right ventricular volume (mL).

    Time frame: 1, 2, and 5 years

  18. Echocardiography - Functional indices - Ejection fraction

    Changes in functional indices - ejection fraction (%).

    Time frame: 1, 2, and 5 years

  19. Echocardiography - Functional indices - Left ventricular strain

    Changes in functional indices - left ventricular strain (%).

    Time frame: 1, 2, and 5 years

  20. Echocardiography - Functional indices - Ventricular velocity

    Changes in functional indices - ventricular velocity (cm/s).

    Time frame: 1, 2, and 5 years

  21. Echocardiography - Functional indices - Right ventricular strain

    Changes in functional indices - right ventricular strain (%).

    Time frame: 1, 2, and 5 years

  22. Echocardiography - Functional indices - Left ventricular stiffness

    Changes in functional indices - left ventricular stiffness.

    Time frame: 1, 2, and 5 years

07

Study locations

1 site
  • Department of Neurology and Clinical Neurophysiology, St Olavs Hospital
    Trondheim, Norway
08

References and documents

Publications

  • Tari AR, Berg HH, Videm V, Brathen G, White LR, Rosbjorgen RN, Scheffler K, Dalen H, Holte E, Haberg AK, Selbaek G, Lydersen S, Duezel E, Bergh S, Logan-Halvorsrud KR, Sando SB, Wisloff U. Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer's disease: protocol for the ExPlas study. BMJ Open. 2022 Sep 6;12(9):e056964. doi: 10.1136/bmjopen-2021-056964. PubMed 36538409 ↗

Individual participant data

Plan to share: Yes — To be decided

Supporting information: Study protocol, Statistical analysis plan

Time frame: After study completion

Access criteria: Collaborative research projects

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Mar 2027, 65 months after the start.

Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's planned 65 months is above that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2021
First posted
Oct 6, 2021
StartActual
Sep 17, 2021
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2031
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05068830
Collaborators
St. Olavs Hospital
Responsible party
Sponsor
First posted
Oct 6, 2021
Start date
Sep 17, 2021
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2031 (estimated)
Last update
Apr 15, 2026

Study contacts

Ulrik Wisløff, PhD, Prof
principal investigator · Cardiac Exercise Research Group at the Department of Circulation and Medical Imaging, NTNU
Sigrid Botne Sando, MD, PhD
principal investigator · Department of Neurology and Clinical Neurophysiology, St. Olavs University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion